Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible, P2Y12 receptor antagonist that inhibits platelet activation and aggregation. It is part of the P2Y12 inhibitor class, distinct from thienopyridines (clopidogrel, prasugrel) due to its reversible binding and lack of a metabolic activation requirement.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** To reduce the rate of cardiovascular thrombotic events, including stent thrombosis, in patients with ACS managed medically or with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
* **Myocardial Infarction (MI):** In patients with a history of MI, to reduce the rate of cardiovascular death, MI, and stroke.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **History of MI (≥ 1 year post-MI):**
* **Maintenance Dose:** 60 mg orally twice daily.
* **Duration of therapy:** Typically 12 months for ACS, or longer based on individual risk assessment and bleeding risk. In patients with a history of MI, continue as long as benefits outweigh risks.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment due to lack of data.
* **Renal Impairment:** No dose adjustment is necessary in patients with mild to moderate renal impairment. Use with caution in severe renal impairment due to limited data.
## Contraindications
* Hypersensitivity to ticagrelor or any of its excipients.
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke (for the 60 mg twice daily indication).
## Adverse Effects
* **Common:** Bleeding (including life-threatening and fatal bleeding, particularly gastrointestinal and intracranial), dyspnea, bradycardia.
* **Serious:** Major bleeding, ventricular pauses, drug-induced lupus.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, ritonavir):** May increase ticagrelor exposure; avoid coadministration or use with caution.
* **Strong CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease ticagrelor exposure; avoid coadministration.
* **Other Antiplatelet Agents and Anticoagulants (e.g., aspirin, clopidogrel, heparin, warfarin):** Increased risk of bleeding. Concomitant use of ticagrelor with aspirin 100 mg or less is generally recommended. Concomitant use with other P2Y12 inhibitors or therapeutic anticoagulation is generally not recommended outside specific clinical scenarios or protocols.
* **Statins:** Ticagrelor can inhibit OATP1B1/1B3 transporters, increasing statin exposure. Consider dose reduction of certain statins (e.g., simvastatin, pravastatin) if coadministered.
* **CYP2C19 Substrates (e.g., omeprazole, esomeprazole):** Ticagrelor can inhibit CYP2C19, potentially increasing concentrations of these drugs.
## Monitoring
* **Bleeding:** Assess for signs and symptoms of bleeding regularly.
* **Bradycardia:** Monitor heart rate, especially in patients with risk factors for bradycardia.
* **Renal and Hepatic Function:** Baseline and periodic monitoring may be warranted depending on clinical status.
## Clinical Pearls
* Ticagrelor is a direct-acting, reversible P2Y12 inhibitor with a rapid onset and offset of action, unlike thienopyridines.
* The recommended maintenance dose in ACS is 90 mg twice daily. For patients with a history of MI who are at least 1 year post-MI and stable, a lower dose of 60 mg twice daily is indicated.
* Dosing of aspirin should be limited to 100 mg or less when used concomitantly in ACS patients to minimize bleeding risk.
* Patients may experience dyspnea, which is typically mild to moderate and transient. If persistent or severe, assess for other causes.
* Discontinuation of ticagrelor may increase the risk of thrombotic events. Premature discontinuation should be avoided unless absolutely necessary due to bleeding concerns or intolerance.
***
*This information is intended for healthcare professionals and is not a substitute for comprehensive prescribing information. Always consult the most current official drug labeling or a qualified healthcare provider for definitive guidance.*
